Please login to the form below

Not currently logged in
Email:
Password:

Strattera

This page shows the latest Strattera news and features for those working in and with pharma, biotech and healthcare.

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who

  • Lilly feels effects of Cymbalta competition Lilly feels effects of Cymbalta competition

    to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

  • Lilly’s Strattera wins new adult ADHD licence in UK Lilly’s Strattera wins new adult ADHD licence in UK

    Lilly’ s Strattera wins new adult ADHD licence in UK. On course for wider EU approval for adults yet to receive treatment. ... Strattera's new licence is backed by results from clinical trials that demonstrate it can achieve significant improvements in

  • Lilly's Strattera patent upheld in US

    The US court of appeals has upheld the validity of Eli Lilly &Company's patent for attention deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine). ... However, the most recent decision upholds Lilly's method-of-use patent which provides

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics